{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T02:11:48Z","timestamp":1774491108534,"version":"3.50.1"},"reference-count":109,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T00:00:00Z","timestamp":1586217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2020.00117","type":"journal-article","created":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T04:41:29Z","timestamp":1586234489000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["New Therapeutic Targets in Autoimmune Cholangiopathies"],"prefix":"10.3389","volume":"7","author":[{"given":"Alessio","family":"Gerussi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Luc\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Cristoferi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Ronca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Milani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daphne","family":"D'Amato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah Elizabeth","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Invernizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,4,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41586-020-2047-9","article-title":"Global chemical effects of the microbiome include new bile-acid conjugations","volume":"579","author":"Quinn","year":"2020","journal-title":"Nature."},{"key":"B2","doi-asserted-by":"publisher","first-page":"E2069","DOI":"10.3390\/ijms19072069","article-title":"Update on FXR biology: promising therapeutic target?","volume":"19","author":"Han","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrg.2016.86","article-title":"Towards precision medicine","volume":"17","author":"Ashley","year":"2016","journal-title":"Nat Rev Genet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"G1124","DOI":"10.1152\/ajpgi.00539.2005","article-title":"Upregulation of a basolateral FXR-dependent bile acid efflux transporter OST\u03b1-OST\u03b2 in cholestasis in humans and rodents","volume":"290","author":"Boyer","year":"2006","journal-title":"Am J Physiol Liver Physiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jcmgh.2018.01.015","article-title":"OST\u03b1-OST\u03b2 guards the ileal enterocyte from the accumulation of toxic levels of bile acids","volume":"5","author":"Boyer","year":"2018","journal-title":"Cell Mol Gastroenterol Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"G923","DOI":"10.1152\/ajpgi.00490.2005","article-title":"Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha\/beta in the adaptive response to bile acids","volume":"290","author":"Zollner","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1159\/000371670","article-title":"Bile acids as hormones: the FXR-FGF15\/19 pathway","volume":"33","author":"Kliewer","year":"2015","journal-title":"Dig Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1128\/MCB.00944-06","article-title":"Coordinated recruitment of histone methyltransferase G9a and other chromatin-modifying enzymes in SHP-mediated regulation of hepatic bile acid metabolism","volume":"27","author":"Fang","year":"2007","journal-title":"Mol Cell Biol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"7707","DOI":"10.1128\/MCB.24.17.7707-7719.2004","article-title":"Role of an mSin3A-Swi\/Snf chromatin remodeling complex in the feedback repression of bile acid biosynthesis by SHP","volume":"24","author":"Kemper","year":"2004","journal-title":"Mol Cell Biol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"15665","DOI":"10.1073\/pnas.0706736104","article-title":"Involvement of corepressor complex subunit GPS2 in transcriptional pathways governing human bile acid biosynthesis","volume":"104","author":"Sanyal","year":"2007","journal-title":"Proc Natl Acad Sci USA."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1053\/j.gastro.2017.01.055","article-title":"Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease","volume":"152","author":"Ch\u00e1vez-Talavera","year":"2017","journal-title":"Gastroenterology."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1172\/JCI64551","article-title":"The TGR5 receptor mediates bile acid-induced itch and analgesia","volume":"123","author":"Alemi","year":"2013","journal-title":"J Clin Invest."},{"key":"B13","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.jhep.2017.01.013","article-title":"Steroidal or non-steroidal FXR agonists - Is that the question?","volume":"66","author":"Verbeke","year":"2017","journal-title":"J Hepatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid x receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.1016\/S0168-8278(17)30608-6","article-title":"A novel farnesoid X receptor agonist: EDP-305, reduces fibrosis progression in animal models of fibrosis","volume":"66","author":"Erstad","year":"2017","journal-title":"J Hepatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrd.2015.9","article-title":"Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23","volume":"15","author":"Degirolamo","year":"2016","journal-title":"Nat Rev Drug Discov."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/S0002-9440(10)61177-7","article-title":"A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice","volume":"160","author":"Nicholes","year":"2002","journal-title":"Am J Pathol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ccr.2011.01.040","article-title":"Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening","volume":"19","author":"Sawey","year":"2011","journal-title":"Cancer Cell."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/hep4.1209","article-title":"NGM282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"2","author":"Mayo","year":"2018","journal-title":"Hepatol Commun."},{"key":"B21","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J Hepatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41575-019-0110-5","article-title":"Better end points needed in primary sclerosing cholangitis trials","volume":"16","author":"Gerussi","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/hep.27744","article-title":"Fibrates and cholestasis","volume":"62","author":"Ghonem","year":"2015","journal-title":"Hepatology."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1002\/hep.25919","article-title":"Liver X receptor \u03b2 and peroxisome proliferator-activated receptor \u03b4 regulate cholesterol transport in murine cholangiocytes","volume":"56","author":"Xia","year":"2012","journal-title":"Hepatology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1038\/nm.2048","article-title":"PPAR-\u03b4 senses and orchestrates clearance of apoptotic cells to promote tolerance","volume":"15","author":"Mukundan","year":"2009","journal-title":"Nat Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/hep.20705","article-title":"Th1 cytokine-induced downregulation of PPAR\u03b3 in human biliary cells relates to cholangitis in primary biliary cirrhosis","volume":"41","author":"Harada","year":"2005","journal-title":"Hepatology."},{"key":"B27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00795-013-0017-0","article-title":"PPAR\u03b3 ligand attenuates portal inflammation in the MRL-lpr mouse: a new strategy to restrain cholangiopathy in primary biliary cirrhosis","volume":"46","author":"Nozaki","year":"2013","journal-title":"Med Mol Morphol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/ajg.2017.287","article-title":"Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response","volume":"113","author":"Reig","year":"2018","journal-title":"Am J Gastroenterol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1007\/s10620-016-4250-y","article-title":"Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC risk score","volume":"61","author":"Hegade","year":"2016","journal-title":"Dig Dis Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1751-2980.2012.00574.x","article-title":"Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy","volume":"13","author":"Han","year":"2012","journal-title":"J Dig Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2174\/1874192401004010120","article-title":"Fenofibrate in primary biliary cirrhosis: a pilot study","volume":"4","author":"Liberopoulos","year":"2010","journal-title":"Open Cardiovasc Med J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/apt.13465","article-title":"Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes","volume":"43","author":"Cheung","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2036.2010.04512.x","article-title":"Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"33","author":"Levy","year":"2011","journal-title":"Aliment Pharmacol Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/hep4.1072","article-title":"The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice","volume":"1","author":"Haczeyni","year":"2017","journal-title":"Hepatol Commun."},{"key":"B35","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S2468-1253(17)30246-7","article-title":"Seladelpar (MBX-8025), a selective PPAR-\u03b4 agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study","volume":"2","author":"Jones","year":"2017","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/jhbp.281","article-title":"Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis","volume":"22","author":"Mizuno","year":"2015","journal-title":"J Hepatobiliary Pancreat Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1007\/s00535-010-0204-x","article-title":"Bezafibrate for the treatment of primary sclerosing cholangitis","volume":"45","author":"Mizuno","year":"2010","journal-title":"J Gastroenterol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1002\/hep.23810","article-title":"The biliary HCO3- umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies","volume":"52","author":"Beuers","year":"2010","journal-title":"Hepatology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.24691","article-title":"A biliary HCO3\u2013 umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes","volume":"55","author":"Hohenester","year":"2012","journal-title":"Hepatology."},{"key":"B40","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/hep.25691","article-title":"Up-regulation of microRNA 506 leads to decreased Cl\u2013\/HCO3\u2013 anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis","volume":"56","author":"Banales","year":"2012","journal-title":"Hepatology."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.jhep.2018.08.020","article-title":"Primary biliary cholangitis: a tale of epigenetically-induced secretory failure?","volume":"69","author":"Rodrigues","year":"2018","journal-title":"J Hepatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1053\/j.gastro.2004.04.009","article-title":"Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice","volume":"127","author":"Fickert","year":"2004","journal-title":"Gastroenterology."},{"key":"B43","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1053\/j.gastro.2005.10.018","article-title":"24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice","volume":"130","author":"Fickert","year":"2006","journal-title":"Gastroenterology."},{"key":"B44","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J Hepatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"CD006000","DOI":"10.1002\/14651858.CD006000.pub2","article-title":"Azathioprine for primary biliary cirrhosis","volume":"18","author":"Gong","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"B46","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/S0168-8278(98)80254-7","article-title":"Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study","volume":"29","author":"Wolfhagen","year":"1998","journal-title":"J Hepatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/01.mcg.0000177235.36640.21","article-title":"Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid","volume":"39","author":"Treiber","year":"2005","journal-title":"J Clin Gastroenterol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJM199005173222003","article-title":"A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis","volume":"322","author":"Wiesner","year":"1990","journal-title":"N Engl J Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/hep.20897","article-title":"Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis","volume":"42","author":"Combes","year":"2005","journal-title":"Hepatology."},{"key":"B50","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","article-title":"Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial","volume":"117","author":"Leuschner","year":"1999","journal-title":"Gastroenterology."},{"key":"B51","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/hep.20646","article-title":"Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: A three-year randomized trial","volume":"41","author":"Rautiainen","year":"2005","journal-title":"Hepatology."},{"key":"B52","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/hep.510310209","article-title":"Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid","volume":"31","author":"Angulo","year":"2000","journal-title":"Hepatology."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis - a comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J Hepatol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/hep.24748","article-title":"Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"55","author":"Tsuda","year":"2012","journal-title":"Hepatology."},{"key":"B55","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/ajg.2013.51","article-title":"B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid","volume":"108","author":"Myers","year":"2013","journal-title":"Am J Gastroenterol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/hep.28359","article-title":"Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: a proof-of-concept study","volume":"64","author":"Hirschfield","year":"2016","journal-title":"Hepatology."},{"key":"B57","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jaut.2019.04.005","article-title":"Therapeutic trials of biologics in primary biliary cholangitis: an open label study of abatacept and review of the literature","volume":"101","author":"Bowlus","year":"2019","journal-title":"J Autoimmun."},{"key":"B58","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat Immunol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B60","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1172\/JCI88881","article-title":"Liver inflammation and fibrosis","volume":"127","author":"Koyama","year":"2017","journal-title":"J Clin Invest."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.bbadis.2017.07.026","article-title":"Pathogenesis of biliary fibrosis","volume":"1864","author":"Pinzani","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis."},{"key":"B62","doi-asserted-by":"publisher","first-page":"68\u20139","DOI":"10.1016\/j.matbio.2018.04.006","article-title":"Liver fibrosis: direct antifibrotic agents and targeted therapies","author":"Schuppan","year":"2018","journal-title":"Matrix Biol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"G1310","DOI":"10.1152\/ajpgi.00365.2011","article-title":"Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2","volume":"302","author":"Miura","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1172\/JCI41732","article-title":"Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice","volume":"120","author":"Berres","year":"2010","journal-title":"J Clin Invest."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/liv.13698","article-title":"Cenicriviroc, a cytokine receptor antagonist, potentiates all-trans retinoic acid in reducing liver injury in cholestatic rodents","volume":"38","author":"Yu","year":"2018","journal-title":"Liver Int."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology."},{"key":"B67","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nri1312","article-title":"NOX enzymes and the biology of reactive oxygen","volume":"4","author":"Lambeth","year":"2004","journal-title":"Nat Rev Immunol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41575-018-0079-5","article-title":"Control and dysregulation of redox signalling in the gastrointestinal tract","volume":"16","author":"Campbell","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/ki.2010.516","article-title":"Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases","volume":"79","author":"Barnes","year":"2011","journal-title":"Kidney Int."},{"key":"B70","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/hep.24465","article-title":"NOX1\/nicotinamide adenine dinucleotide phosphate, reduced form (NADPH) oxidase promotes proliferation of stellate cells and aggravates liver fibrosis induced by bile duct ligation","volume":"54","author":"Cui","year":"2011","journal-title":"Hepatology."},{"key":"B71","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.freeradbiomed.2012.05.007","article-title":"Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4\/NOX1 inhibitor in vivo","volume":"53","author":"Jiang","year":"2012","journal-title":"Free Radic Biol Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1111\/liv.13221","article-title":"Gamma-glutamyltransferase-friend or foe within?","volume":"36","author":"Kunutsor","year":"2016","journal-title":"Liver Int."},{"key":"B73","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1056\/NEJMra1600266","article-title":"The human intestinal microbiome in health and disease","volume":"375","author":"Lynch","year":"2016","journal-title":"N Engl J Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41575-018-0061-2","article-title":"You are what you eat: diet, health and the gut microbiota","volume":"16","author":"Zmora","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"j5145","DOI":"10.1136\/bmj.j5145","article-title":"The role of the gut microbiome in systemic inflammatory disease","volume":"360","author":"Clemente","year":"2018","journal-title":"BMJ."},{"key":"B76","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41575-018-0011-z","article-title":"Erratum to: the gut-liver axis and the intersection with the microbiome (Nature Reviews Gastroenterology & Hepatology","volume":"15","author":"Tripathi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/apt.14397","article-title":"Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease","volume":"47","author":"Woodhouse","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"key":"B78","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1136\/gutjnl-2016-313332","article-title":"Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy","volume":"67","author":"Tang","year":"2018","journal-title":"Gut."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1136\/gutjnl-2015-311004","article-title":"Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD","volume":"65","author":"Sabino","year":"2016","journal-title":"Gut"},{"key":"B80","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1177\/2050640619876787","article-title":"The gut virome in inflammatory bowel disease pathogenesis: from metagenomics to novel therapeutic approaches","volume":"7","author":"Ungaro","year":"2019","journal-title":"United Eur Gastroenterol J."},{"key":"B81","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1136\/gutjnl-2018-317791","article-title":"Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis","volume":"69","author":"Lemoinne","year":"2019","journal-title":"Gut"},{"key":"B82","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/hep.27927","article-title":"Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis","volume":"63","author":"Tabibian","year":"2016","journal-title":"Hepatology."},{"key":"B83","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1055\/s-0037-1608801","article-title":"The microbiome in primary sclerosing cholangitis: current evidence and potential concepts","volume":"37","author":"Hov","year":"2017","journal-title":"Semin Liver Dis."},{"key":"B84","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/apt.12232","article-title":"Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study","volume":"37","author":"Tabibian","year":"2013","journal-title":"Aliment Pharmacol Ther."},{"key":"B85","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/ajg.2008.14","article-title":"Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study","volume":"104","author":"Silveira","year":"2009","journal-title":"Am J Gastroenterol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"457","DOI":"10.15403\/jgld.2014.1121.254.rah","article-title":"A triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study","volume":"25","author":"Rahimpour","year":"2016","journal-title":"J Gastrointest Liver Dis."},{"key":"B87","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1126\/science.aaz3834","article-title":"Are noncommunicable diseases communicable?","volume":"367","author":"Finlay","year":"2020","journal-title":"Science (80-)"},{"key":"B88","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.cell.2011.04.022","article-title":"NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis","volume":"145","author":"Elinav","year":"2011","journal-title":"Cell."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1038\/s41591-018-0238-9","article-title":"Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Nat Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1053\/j.gastro.2019.04.053","article-title":"Fecal microbial transplantation for diseases beyond recurrent clostridium difficile infection","volume":"157","author":"D'Haens","year":"2019","journal-title":"Gastroenterology."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1053\/j.gastro.2018.12.019","article-title":"Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent clostridium difficile infection","volume":"156","author":"Hvas","year":"2019","journal-title":"Gastroenterology."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","article-title":"Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial","volume":"114","author":"Allegretti","year":"2019","journal-title":"Am J Gastroenterol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1126\/science.aad0135","article-title":"A gut-vascular barrier controls the systemic dissemination of bacteria","volume":"350","author":"Spadoni","year":"2015","journal-title":"Science (80-)"},{"key":"B94","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1053\/j.gastro.2015.10.046","article-title":"Leukocyte trafficking to the small intestine and colon","volume":"150","author":"Habtezion","year":"2016","journal-title":"Gastroenterology."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1053\/jhep.2001.24231","article-title":"MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease)","volume":"33","author":"Grant","year":"2001","journal-title":"Hepatology."},{"key":"B96","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.cgh.2019.05.013","article-title":"Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases","volume":"18","author":"Lynch","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1136\/gutjnl-2016-312354","article-title":"Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner","volume":"67","author":"Trivedi","year":"2018","journal-title":"Gut."},{"key":"B98","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.autrev.2018.02.013","article-title":"Support of precision medicine through risk-stratification in autoimmune liver diseases - histology, scoring systems, and non-invasive markers","volume":"17","author":"Bossen","year":"2018","journal-title":"Autoimmun Rev."},{"key":"B99","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrg.2018.4","article-title":"Integrative omics for health and disease","volume":"19","author":"Karczewski","year":"2018","journal-title":"Nat Rev Genet"},{"key":"B100","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/nrgastro.2017.103","article-title":"Liver cancer: translating \u201c-omics\u201d results into precision medicine for hepatocellular carcinoma","volume":"14","author":"Sia","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41591-019-0414-6","article-title":"A longitudinal big data approach for precision health","volume":"25","author":"Sch\u00fcssler-Fiorenza Rose","year":"2019","journal-title":"Nat Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41540-017-0009-0","article-title":"Integrating personalized gene expression profiles into predictive disease-associated gene pools","volume":"3","author":"Menche","year":"2017","journal-title":"NPJ Syst Biol Appl."},{"key":"B103","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41586-019-1236-x","article-title":"Longitudinal multi-omics of host-microbe dynamics in prediabetes","volume":"569","author":"Zhou","year":"2019","journal-title":"Nature."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.cell.2012.02.009","article-title":"Personal omics profiling reveals dynamic molecular and medical phenotypes","volume":"148","author":"Chen","year":"2012","journal-title":"Cell."},{"key":"B105","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/jama.2019.5791","article-title":"Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis","volume":"321","author":"Seymour","year":"2019","journal-title":"JAMA."},{"key":"B106","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","article-title":"Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables","volume":"6","author":"Ahlqvist","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41591-018-0300-7","article-title":"High-performance medicine: the convergence of human and artificial intelligence","volume":"25","author":"Topol","year":"2019","journal-title":"Nat Med."},{"key":"B108","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/s42256-019-0139-8","article-title":"Validity of machine learning in biology and medicine increased through collaborations across fields of expertise","volume":"38","author":"Littmann","year":"2020","journal-title":"Nat Mach Intell"},{"key":"B109","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/liv.13744","article-title":"Time for the dawn of multimodal therapies and the dusk for mono-therapeutic trials for cholestatic liver diseases?","volume":"38","author":"Wagner","year":"2018","journal-title":"Liver Int."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2020.00117\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T04:41:31Z","timestamp":1586234491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2020.00117\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,7]]},"references-count":109,"alternative-id":["10.3389\/fmed.2020.00117"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2020.00117","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,7]]},"article-number":"117"}}